Introduction {#s1}
============

Colorectal cancer (CRC) is one of the main forms of cancer, being the second most frequent neoplasm in both sexes and one of the most important morbidity causes in the western world [@pone.0012673-Ferlay1]. The genetic contribution to CRC has been estimated to be around 35% by extensive twin studies [@pone.0012673-Lichtenstein1]. However, highly penetrant variants, that cause mendelian predisposition syndromes, account only for, at most, 5% of the disease cases [@pone.0012673-delaChapelle1]. The remaining genetic susceptibility is thought to follow a polygenic model, with an interplay of multiple low-penetrance allelic variants appearing in high frequency in the general population, and each conferring a modest effect on disease risk [@pone.0012673-Castells1], [@pone.0012673-Houlston1].

Candidate-gene studies have been one of the most commonly used tools in the screening for new variants affecting CRC risk. Gene selection in these studies is mainly based on the functional implications of a possible association, and thus genes selected have either been chosen because of the previous presence of other high/low risk alleles [@pone.0012673-Chen1], or their participation in a pathway implicated in the pathogenesis of the disease [@pone.0012673-Naccarati1]. Candidate-gene studies can be performed by either direct approaches, where the variants genotyped are presumed to be the underlying cause of the disease because of their location (variants in exonic or regulatory regions), or by indirect approaches, where tag SNPs take advantage of the linkage disequilibrium properties of the human genome to try and screen the most of the variability in a given gene.

This latter approach has also allowed, together with the development of high-throughput technologies, the implementation of new hypothesis-free approaches (in opposition with hypothesis-based candidate-gene approaches), covering the majority of the genome (genome-wide association studies or GWAS). This implementation has successfully led to the identification of some new susceptibility loci [@pone.0012673-Houlston2]--[@pone.0012673-Tenesa1], including rs4444235 and rs9929218, that fall within reach of two genes belonging to the BMP pathway. Nevertheless, these have been found to predict only a small proportion of the disease susceptibility, with the remaining yet to be discovered [@pone.0012673-Cazier1].

We hence aimed to find such susceptibility variants through a candidate-gene approach screening a selected number of variants within two cellular pathways that have consistently been linked to CRC tumorogenesis: the Wnt and the BMP signaling pathways [@pone.0012673-Segditsas1], [@pone.0012673-Huang1].

The Wnt pathway contains genes that have for long been known to be responsible of some hereditary CRC syndromes, such as *APC* and familial adenomatous polyposis [@pone.0012673-Half1]. Moreover, somatic alterations in *APC* are found in almost 80% of the sporadic colorectal cancers, and Wnt signaling activation is involved in the best part of sporadic colorectal carcinomas [@pone.0012673-Rowan1]. On the other hand, the BMP pathway acts as positive regulator of some of the Wnt proteins [@pone.0012673-Huang1], and the tumor suppressive role of this signaling pathway in the pathogenesis of CRC and other cancers is well established [@pone.0012673-Deng1], [@pone.0012673-Deng2]. Besides, mutations in two of its genes, *SMAD4* and *BMPR1A*, are responsible for juvenile polyposis syndrome, another hereditary CRC condition [@pone.0012673-Chen2]. Considering all this information, we thought it would be interesting to screen some of the genetic variability within these pathways for any evidence of new CRC related variants that could explain at least part of the missing heritability. Our approach was mainly functional, for only SNPs within exonic or *cis*-regulatory sequences (5′ and 3′ unstranslated regions) were selected to analyse their relationship with CRC susceptibility.

Results and Discussion {#s2}
======================

Following our pathway-based candidate-gene selection method, we performed our study in a total of 45 SNPs that were in either exonic or regulatory regions, in an overall of 21 genes from both the Wnt and BMP pathways. Details of SNP features and association values for the 37 SNPs that successfully passed quality control criteria are shown on [Table 1](#pone-0012673-t001){ref-type="table"}. None of the screened SNPs were significantly associated with an altered risk of CRC, considering odds-ratios and related p values for allelic and genotypic tests (trend, dominant and recessive). Logistic regression for age and sex adjustment was performed, although it did not improve p value results. Haplotype analysis results were consistent in both Unphased and Haploview, and did not show any signs of positive associations either for any of the 8 genes for which this analysis was performed (*AXIN1*, *HDAC9*, *BMP4*, *DACT1*, *CDH3*, *CDH1*, *BTRC*, and *APC)*, ([Figure S1](#pone.0012673.s001){ref-type="supplementary-material"}). Stratification analysis comparing sporadic and familial cases was also implemented, but it did not provide any evidence of differences in susceptibilities between the groups that could be a sign of any specific associations within either of the groups ([Table 2](#pone-0012673-t002){ref-type="table"}).
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###### Description of the 37 SNPs that passed quality control criteria and their associated p values.

![](pone.0012673.t001){#pone-0012673-t001-1}

  Gene          SNP ID      SNP type    Amino acid change   Allele    MAF cases   MAF controls   GT counts cases   GT counts controls   p-value                      OR (95% CI)
  ---------- ------------ ------------ ------------------- --------- ----------- -------------- ----------------- -------------------- --------- ----------------------------------------------------
  *ADAR*      rs2229857     Missense          K384R         **A**/G    0.3306        0.3201        99/360/385          88/347/382        0.512                    1.05 (0.91--1.22)
  *APC*       rs2229992    Synonymous         Y486Y         C/**T**    0.3981        0.4125        145/382/317        141/392/284       0.3728                    0.94 (0.82--1.08)
  *APC*        rs351771    Synonymous         A545A         **C**/T    0.3817        0.375         124/397/324        125/416/347       0.7978                    1.02 (0.89--1.18)
  *APC*        rs41115     Synonymous        T1493T         **C**/T    0.3796        0.3761        126/385/328        127/414/347       0.8595                    1.00 (0.88--1.16)
  *APC*        rs42427     Synonymous        G1678G         A/**G**    0.3741        0.3713        124/382/336        116/365/323       0.9252                    1.01 (0.88--1.17)
  *APC*        rs459552     Missense         V1822D         **A**/T    0.2302        0.2134        48/293/504          41/297/550       0.2197                    1.11 (0.94--1.30)
  *APC*        rs465899    Synonymous        P1960P         **C**/T    0.3828        0.3743        126/395/324        125/414/348       0.7107                    1.03 (0.90--1.19)
  *APC*        rs866006    Synonymous        S1756S         **A**/C    0.3775        0.3756        123/370/323        124/401/339        0.925                    1.00 (0.87--1.19)
  *AXIN1*     rs1805105    Synonymous         D254D         C/**T**    0.3918        0.4096        136/387/318        164/397/324       0.2692                    0.93 (0.81--1.07)
  *AXIN1*      rs214250    Synonymous         S428S         C/**T**    0.2206        0.2028        32/307/502          34/265/522       0.2138                    1.12 (0.94--1.32)
  *AXIN1*      rs214252    Synonymous         A609A         A/**G**    0.2207        0.2005        32/305/499          34/258/521       0.1403                    1.13 (0.96--1.34)
  *AXIN1*      rs400037     Missense          R388Q         C/**T**    0.1826        0.1829        27/244/545          39/234/580       0.8972                    1.04 (0.87--1.24)
  *AXIN2*     rs2240308     Missense          P50S          **A**/G    0.4502        0.4219        168/423/252        152/442/290       0.1031                    1.11 (0.97--1.27)
  *BMP4*       rs17563      Missense          V152A         C/**T**    0.4946        0.4855        211/407/220        208/420/233       0.5498                    1.07 (0.93--1.23)
  *BMP4*      rs4444235        --              --           C/**T**    0.4563        0.4557        168/436/242        196/411/274       0.9343    0.99 (0.86--1.14)[\*](#nt103){ref-type="table-fn"}
  *BTRC*      rs17767748   Synonymous         I229I         C/**T**    0.05516       0.056          3/86/745            4/91/789        0.9324                    1.00 (0.74--1.36)
  *BTRC*      rs4151060     Missense          A543S         G/**T**    0.04793      0.04904         4/73/768            2/83/802        0.6997                    0.96 (0.70--1.32)
  *CCND1*      rs603965    Synonymous         P241P         **A**/G    0.4969        0.4822        204/406/209        206/430/237       0.4164                    1.06 (0.93--1.22)
  *CDH1*      rs1801552    Synonymous         A692A         C/**T**    0.3547        0.3781        105/371/343        126/365/325       0.1834                    0.92 (0.81--1.07)
  *CDH1*      rs9929218     Intronic           --           **A**/G    0.2811        0.2873        65/345/435          83/342/459       0.5486    0.97 (0.83--1.13)[\*](#nt103){ref-type="table-fn"}
  *CDH3*      rs1126933     Missense          Q563H         **C**/G    0.3828        0.3802        129/382/325        129/361/324       0.8369                    1.02 (0.88--1.17)
  *CDH3*      rs17715450   Synonymous         R747R         A/**C**    0.3783        0.3959        116/390/316        147/402/330       0.2792                    0.93 (0.80--1.07)
  *CDH3*      rs2274239    Synonymous         K652K         **C**/T    0.3599        0.3771        108/390/344        126/368/328       0.2863                    0.93 (0.81--1.07)
  *CDH3*      rs2296408    Synonymous         T271T         **G**/T    0.3698        0.3724        107/394/321        130/388/352       0.8768                    1.00 (0.87--1.15)
  *CDH3*      rs2296409    Synonymous         T240T         **C**/T    0.3585        0.3643        106/391/344        130/387/371       0.7962                    0.98 (0.85--1.13)
  *CDH3*      rs8049247    Synonymous         I204I         **A**/C    0.1665        0.1682        21/238/582          22/249/600       0.8683                    0.97 (0.81--1.17)
  *DACT1*     rs17832998    Missense          A464V         C/**T**    0.3468        0.3448        111/362/369        116/381/392       0.9293                    1.01 (0.88--1.17)
  *DACT1*      rs863091    Synonymous         V378V         C/**T**    0.2047        0.2033        30/283/525          41/249/524        0.932                    1.01 (0.85--1.19)
  *HDAC9*     rs1178127     Missense          P621P         A/**G**     0.21         0.2203        37/273/516          41/300/526       0.4737                    0.94 (0.80--1.12)
  *HDAC9*     rs34096894   Synonymous         L152L         C/**T**    0.01953      0.01351         0/33/812            1/22/865        0.2075                    1.33 (0.78--2.27)
  *NLK*       rs3182380    Synonymous         I498I         C/**T**    0.05142      0.05535         2/83/761            3/85/734        0.4686                    0.92 (0.68--1.24)
  *PPARD*     rs2076167    Synonymous         N163N         A/**G**    0.2956        0.294         72/355/417          78/328/417       0.9891                    1.00 (0.86--1.16)
  *SMURF1*     rs219797    Synonymous         S166S         C/**G**    0.4452        0.4712        160/428/252        210/415/261       0.1591                    0.90 (0.78--1.03)
  *TCF7*       rs30489      Missense          G256R         C/**T**    0.07683      0.07937         6/118/722          6/128/748        0.7655                    0.97 (0.75--1.25)
  *TLE1*      rs2228173    Synonymous         E118E         **A**/G    0.1183        0.1172        11/178/656          6/196/685         0.992                    1.02 (0.82--1.26)
  *WIF1*      rs7301320    Synonymous         A73A          C/**T**    0.2237        0.2219        48/265/494          47/281/517       0.9768                    1.00 (0.84--1.18)
  *WNT2B*      rs910697    Synonymous         Q390Q         A/**G**    0.4218        0.4301        154/404/286        172/419/296       0.5463                    0.95 (0.83--1.09)

Minor allele is depicted in bold.

MAF. Minor Allele Frequency; OR 95% CI. Odds Ratio and 95% Confidence Interval. GT counts. Genotype counts.

\**Described OR (95%CI) for rs4444235 and rs9929218 were 1.11 (1.08--1.15) and 0.91 (0.89--0.94), respectively, as taken from Houlston et al.. Nat Genet 2008*.

10.1371/journal.pone.0012673.t002

###### Association values for stratified analysis in familial and sporadic CRC groups.

![](pone.0012673.t002){#pone-0012673-t002-2}

                           Familial vs control   Sporadic vs control   Familial vs sporadic                                
  ---------- ------------ --------------------- --------------------- ---------------------- ------------------- --------- -------------------
  *ADAR*      rs2229857          0.08586          1.28 (0.97--1.68)           0.8662          1.01 (0.87--1.18)   0.1011    1.26 (0.95--1.67)
  *APC*       rs2229992          0.6564           1.06 (0.81--1.39)           0.2732          0.92 (0.80--1.07)   0.3214    1.15 (0.87--1.51)
  *APC*        rs351771          0.3266           1.15 (0.87--1.50)           0.8956          1.01 (0.87--1.17)   0.3659    1.14 (0.86--1.49)
  *APC*        rs41115           0.4254           1.12 (0.85--1.47)           0.9802          1.00 (0.86--1.15)   0.4306    1.12 (0.85--1.47)
  *APC*        rs42427           0.3978           1.13 (0.86--1.48)           0.9322          0.99 (0.86--1.15)   0.3825    1.13 (0.86--1.49)
  *APC*        rs459552          0.05147          1.35 (1.00--1.83)           0.4821          1.06 (0.90--1.26)   0.1313    1.27 (0.93--1.72)
  *APC*        rs465899          0.3161           1.15 (0.88--1.51)           0.8003          1.02 (0.88--1.18)   0.3885    1.13 (0.86--1.49)
  *APC*        rs866006          0.3634           1.14 (0.86--1.49)           0.8589          0.99 (0.85--1.14)   0.3256    1.15 (0.87--1.52)
  *AXIN1*     rs1805105          0.0674           0.77 (0.58--1.02)           0.5492          0.96 (0.83--1.10)   0.1524    0.81 (0.61--1.08)
  *AXIN1*      rs214250          0.5041           1.12 (0.81--1.55)           0.2312          1.11 (0.93--1.32)   0.9975    1.00 (0.72--1.39)
  *AXIN1*      rs214252          0.4511           1.13 (0.82--1.57)           0.1736          1.13 (0.95--1.34)   0.9984    1.00 (0.72--1.39)
  *AXIN1*      rs400037          0.1971           1.25 (0.89--1.74)           0.6545          0.96 (0.80--1.15)   0.1447    1.29 (0.92--1.81)
  *AXIN2*     rs2240308          0.7901           1.04 (0.78--1.36)           0.0733          1.14 (0.99--1.31)   0.5069    0.91 (0.69--1.20)
  *BMP4*       rs17563           0.1037           1.25(0.95--1.64)            0.9434          1.01 (0.87--1.16)   0.1119    1.25 (0.95--1.64)
  *BMP4*      rs4444235          0.2311           0.85 (0.65--1.11)           0.6689          1.03 (0.90--1.19)   0.1486    0.82 (0.62--1.08)
  *BTRC*      rs17767748         0.7285           1.10 (0.63--1.93)           0.813           0.96 (0.71--1.31)   0.6361    1.15 (0.65--2.03)
  *BTRC*      rs4151060          0.1176           1.52 (0.90--2.57)           0.4741          0.89 (0.64--1.24)   0.04729   1.72 (1.00--2.96)
  *CCND1*      rs603965           0.335           0.87 (0.66--1.15)           0.2045          1.10 (0.95--1.26)   0.1203    0.80 (0.61--1.06)
  *CDH1*      rs1801552          0.6563           1.07 (0.80--1.41)          0.08919          0.88 (0.76--1.02)   0.1812    1.21 (0.91--1.61)
  *CDH1*      rs9929218          0.8686           0.98 (0.73--1.31)           0.6861          0.97 (0.83--1.13)    0.926    1.01 (0.75--1.37)
  *CDH3*      rs1126933          0.1283           1.23 (0.94--1.62)           0.7438          0.98 (0.84--1.13)   0.09059   1.27 (0.96--1.67
  *CDH3*      rs17715450         0.2767           0.86 (0.65--1.13)           0.4126          0.94 (0.82--1.09)   0.5064    0.91 (0.68--1.21)
  *CDH3*      rs2274239          0.1972           0.83 (0.63--1.10)           0.4589          0.95 (0.82--1.10)   0.3649    0.88 (0.66--1.17)
  *CDH3*      rs2296408          0.4447           0.90 (0.68--1.19)           0.9386          1.01 (0.87--1.16)   0.4216    0.89 (0.67--1.18)
  *CDH3*      rs2296409          0.1256           0.80 (0.60--1.07)           0.9158          1.01 (0.87--1.17)   0.1138    0.79 (0.59--1.06)
  *CDH3*      rs8049247          0.9636           1.01 (0.71--1.44)           0.867           0.98 (0.82--1.19)   0.9021    1.02 (0.71--1.47)
  *DACT1*     rs17832998         0.9185           0.99 (0.74--1.31)           0.8619          1.01 (0.88--1.17)   0.8392    0.97 (0.73--1.29)
  *DACT1*      rs863091          0.5683           0.90 (0.64--1.28)           0.7737          1.03 (0.86--1.22)   0.4595    0.88 (0.62--1.24)
  Gene          SNP ID           p-value             OR (CI 95%)             p-value             OR (CI 95%)      p-value      OR (CI 95%)
  *HDAC9*     rs1178127          0.8693           1.03 (0.74--1.42)           0.3847          0.93 (0.78--1.10)   0.5511    1.11 (0.80--1.54)
  *HDAC9*     rs34096894         0.8555           0.89 (0.27--2.99)           0.1093          1.55 (0.90--2.67)   0.3638    0.58 (0.18--1.91)
  *NLK*       rs3182380          0.4747           0.79 (0.42--1.50)           0.7387          0.95 (0.69--1.30)   0.5917    0.84 (0.44--1.60
  *PPARD*     rs2076167          0.1051           0.77 (0.57--1.06)           0.5291          1.05 (0.90--1.23)   0.06342   0.74 (0.55--1.02)
  *SMURF1*     rs219797          0.9123           0.99 (0.75--1.29)          0.09224          0.89 (0.77--1.02)   0.4764    1.10 (0.84--1.45)
  *TCF7*       rs30489           0.1722           1.36 (0.87--2.11)           0.4351          0.90 (0.69--1.17)   0.07095   1.51 (0.96--2.38)
  *TLE*       rs2228173          0.4715           1.16 (0.78--1.71)           0.8995          0.99 (0.79--1.23)   0.4626    1.16 (0.78--1.73)
  *WIF1*      rs7301320          0.2681           1.20 (0.87--1.64)           0.8226          0.98 (0.83--1.16)   0.2418    1.21 (0.88--1.67)
  *WNT2B*      rs910697          0.4228           0.90 (0.68--1.17)           0.7713          0.98 (0.85--1.13)   0.5418    0.92 (0.70--1.21)

MAF. Minor Allele Frequency; OR 95% CI. Odds Ratio and 95% Confidence Interval.

Thus, our strategy has not managed to detect any new susceptibility loci for CRC risk.

Pathway-based expectations have proved to be quite discouraging in the literature as well, for strong candidate pathways, such as DNA-repair ones, surprisingly failed too in identifying any new risk variants [@pone.0012673-Naccarati1], [@pone.0012673-Tao1]--[@pone.0012673-Schafmayer1]. In addition to this, most of the genetic variants that have been found to be associated with disease are located in intergenic regions, with potential functions that are yet unknown.

Still, in light of the recent discoveries that followed up the analysis of genome-wide data, both Wnt and BMP have earned a renewed fame. The susceptibility locus found on 8q24 (rs6983267) has been linked to an enhanced Wnt signaling through its interaction with TCF4 [@pone.0012673-Pomerantz1], [@pone.0012673-Tuupanen1], and a meta-analysis conducted on a series of GWAS data succeeded in associating two variants in the *BMP4* and *CDH1* gene regions with the disease (rs4444235 and rs9929218, respectively)[@pone.0012673-Houlston2].

Even though this is actually the first association study that considers the pathways as a whole for gene selection, some of the genes included in our analysis (i.e *APC, CCND1*, *CDH1* and *TCF7*) had already been screened for risk alleles [@pone.0012673-Chen1], [@pone.0012673-Picelli1]--[@pone.0012673-Hazra1]. It is quite remarkable that there has been a growing debate over some of these loci, specially the p.V1822D variant in *APC* (rs459552). This missense change is widely documented in the literature, with some studies defending it as neutral (this study and others)[@pone.0012673-RuizPonte1], and some conferring its minor allele a protective effect [@pone.0012673-Chen1], [@pone.0012673-Slattery1]. Lack of appropriate study power, resultant from insufficient number of samples has been a major problem in many of these studies and thus most of them have not provided very convincing results [@pone.0012673-Kemp1].

Although our study had over 80% power to detect OR as low as 1.21 with minor allele frequencies of 0.30 (57% of our SNPs), and 1.24 for MAFs down to 0.2 (78% of the SNPs), assuming a log-additive model and α = 0.05, we were unable to detect any positive associations suggesting the presence of any new CRC susceptibility variants. Nevertheless, it is quite remarkable that, albeit our failure to replicate the associations for the *BMP4* and *CDH1* SNPs, this is the first study that investigates any of the so-called 10 new GWAS-discovered susceptibility loci in a Southern-European population.

Despite our negative results, we must consider that we did not whatsoever comprehensively cover all possible low-penetrance variants within the selected genes. This is mainly due to the fact that our strategy was purely functional, selecting the variants that were *a priori* good candidates to be directly associated with the disease. This indeed may constitute a limitation in the study, for most of the genetic variation within the loci was not investigated. Thus, we believe further efforts should be made to screen a wider variety of loci within these pathways, specially considering the previous positive associations described so far for both Wnt and BMP-related genes.

Pondering the potential odds ratios of the variants described so far (1.11, CI 1.08--1.15 and 0.91, CI 0.89--0.94 for rs4444235 and rs9929218, respectively), we assume larger cohorts may be required to detect such subtle effects. On the other hand, when considering candidate-gene approaches, it would also be useful to meta-analyse previous studies and pull the information across of them altogether in the search of evidences of potential new pathways linked to the pathogenesis of the disease.

Materials and Methods {#s3}
=====================

Study populations {#s3a}
-----------------

Subjects were 933 CRC patients and 969 controls that belonged to the EPICOLON project, a prospective, multicentre, population-based epidemiology survey studying the incidence and features of familial and sporadic CRC in the Spanish population [@pone.0012673-Pinol1]. Cases were selected across 11 hospitals in Spain as all patients with a *de-novo* histologically confirmed diagnosis of colorectal adenocarcinoma and who attended 11 community hospitals across Spain between November 2006 and December 2007. Patients in whom CRC developed in the context of familial adenomatous polyposis or inflammatory bowel disease, and cases where patients or family refused to participate in the study were excluded. Demographic, clinical and tumour-related characteristics of probands, as well as a detailed family history were obtained using a pre-established questionnaire, and registered in a single database. Of these, 592 (63%) were male and 341 (37%) female. Median age for cases was 73 (range 26--95), whereas mean was 71(SD±10.7). Hospital-based controls were recruited together with cases and were confirmed to have no cancer or prior history of neoplasm, and no family history of CRC. All controls were randomly selected and matched with cases for sex and age (±5 years) in a 1∶1 ratio. Both cases and controls were of European ancestry and from Spain.

Ethics statement {#s3b}
----------------

The study was approved by the "Comité Ético de Investigación Clínica de Galicia", and each of the institutional review boards of the hospitals where samples were collected ("Ethics Committee of the Hospital Clínic-Barcelona", "Ethics Committee of the Hospital del Mar-Barcelona", "Ethics Committee of the Hospital German Trias i Pujol-Barcelona", "Ethics Committee of the Hospital Sant Pau-Barcelona," "Ethics Committee of the Hospital Universitari Arnau de Vilanova-Lleida", "Ethics Committee of the Hospital General-Alicante", "Ethics Committee of the Hospital de Donosti", "Ethics Committee of the Hospital General de Asturias-Oviedo", "Ethics Committee of the Hospital Clinico-Zaragoza", "Ethics Committee of the Hospital de Calahorra-La Rioja", "Ethics Committee of the Hospital Meixoeiro-Vigo"). All samples were obtained with written informed consent reviewed by the ethical board of the corresponding hospital.

DNA extraction {#s3c}
--------------

DNA was obtained from frozen peripheral blood; extraction was performed in a CHEMAGEN robot (Chemagen Biopolymer-Technologie AG, Baesweiler, Germany) in accordance with the manufacturer\'s instructions, at the Galician Public Fundation of Genomic Medicine in Santiago de Compostela. Cases and controls were extracted in mixed batches to avoid any kind of bias.

Candidate-gene selection {#s3d}
------------------------

Both Wnt and BMP pathways were initially selected after the findings of Nishanian et al. [@pone.0012673-Nishanian1], who demonstrated the interaction between these two pathways. Both pathways were thoroughly investigated through the Cancer Genome Anatomy Project site [@pone.0012673-The1], but we failed to find any information regarding the BMP pathway in either this or other web browsers. For that reason, Wnt genes were selected by browsing the pathway through Biocarta [@pone.0012673-Biocarta1], whereas BMP genes had to be strictly selected from previous literature [@pone.0012673-Huang1], [@pone.0012673-Nishanian1]. Forty-one genes were finally selected to be included in the analysis.

SNP selection and genotyping {#s3e}
----------------------------

SNP selection criteria only considered functional markers with minor allele frequencies above 0.05 and at least two independent validation criteria as established in dbSNP [@pone.0012673-126dbSNP1]. This included all exonic variants selected with Pupasuite [@pone.0012673-Conde1] and gene-regulatory regions in *cis* (5′or 3′ UTR ends), as defined by the FESD web browser [@pone.0012673-Kang1]. 5′UTR variants were only included when they complied to the abovementioned criteria and were presumed to be in the potential binding site of a known transctiptional binding factor. 3′ UTR variants were included because of their potential relationship with miRNA binding regions [@pone.0012673-Jackson1]. Because some of the selected genes had no SNPs of such these kinds in any of the three browsers at the time of SNP selection, they ultimately had to be dropped out of the study. Finally, 43 SNPs were chosen within 21 genes to be screened as potential direct modifiers of CRC susceptibility ([Table 3](#pone-0012673-t003){ref-type="table"}).

10.1371/journal.pone.0012673.t003

###### Description of all genes selected from both pathways and SNPs screened within each of them.

![](pone.0012673.t003){#pone-0012673-t003-3}

  Gene Name                                                                                                                          Function                                                 pathway/genes modulated by BMP signalling                          SNPs selected
  ----------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ------------------------------------------- --------------------------------------------------------------
  ***ADAR,*** **Adenosine deaminase, RNA- specific**                                   Converts multiple adenosines to inosines and creates I/U mismatched base pairs in double-helical RNA              Wnt signalling^36^                                        rs2229857
  ***APC,*** **Adenomatous Polyposis Coli**                                                                                   B-catenin degradation                                                      Wnt signalling^36^                rs2229992,rs351771,rs4115,rs42427rs459552,rs465899,rs86006
  ***AXIN1*** **, Axin 1**                                                                                                     B-catenin regulation                                                      Wnt signalling^36^                 rs1048786,rs1805105,rs214250,rs214252,rs400037,rs419949
  ***BTRC*** **, Beta-transducin repeat containing**                                                                         B-catenin ubiquitination                                                    Wnt signalling^36^                                   rs17767748,rs415060
  ***CCND1*** **, Cyclin D1**                                                                                                   Cell cycle control                                                       Wnt signalling^36^                                         rs603965
  *CSNK1A1*, Casein kinase 1, alpha 1                                                                                        B-catenin fosforilation                                                     Wnt signalling^36^                                            NA
  *CSNK2A1*, Casein kinase 2, alpha 1                                                                                        B-catenin fosforilation                                                     Wnt signalling^36^                                            NA
  *CTBP1*, C-terminal binding protein 1                                                                        Transcriptional repressor in cellular proliferation                                       Wnt signalling^36^                                            NA
  *CTNNB1*, Catenin (cadherin-associated protein), beta 1                                                             Cell adhesion and signal transduction                                              Wnt signalling^36^                                            NA
  *EIF4E*, Eukaryotic translation initiation factor 4E                                                                    Translation initiation factor                                                  Wnt signalling^36^                                            NA
  *ELAC1*, ElaC homolog 1 (E. coli)                                                                                           Zinc phosphodiesterase                                                     Wnt signalling^36^                                            NA
  *FRAT1*, Frequently rearranged in advanced T-cell lymphomas                                                                B-catenin stabilization                                                     Wnt signalling^36^                                            NA
  *FZD1*, Frizzled homolog 1 (Drosophila)                                                                                   Receptor for Wnt proteins                                                    Wnt signalling^36^                                            NA
  ***GSK3B*** **, Glycogen synthase kinase 3 beta**                                                                          B-catenin fosforilation                                                     Wnt signalling^36^                                        rs34002644
  ***HDAC9*** **, Histone deacetylase 9**                                                                             Transcriptional regulation, cell cycle                                             Wnt signalling^36^                                   rs1178127,rs34096894
  ***HNF4A*** **, Hepatocyte nuclear factor 4, alpha**                                                          Transcriptionally controlled transcription factor                                        Wnt signalling^36^                                        rs35078168
  *MAP3K7*, Mitogen-activated protein kinase kinase kinase 7                                                          Signaling transduction induced by BMP                                              Wnt signalling^36^                                            NA
  *MYC*, v-myc myelocytomatosis viral oncogene homolog (avian)                                                           Regulation of gene transcription                                                Wnt signalling^36^                                            NA
  ***NLK*** **, Nemo-like kinase**                                                                                      Negatively regulation wnt pathway                                                Wnt signalling^36^                                        rs3182380
  ***PPARD*** **, Peroxisome proliferator-activated receptor delta**                                                  Ligand-activated transcription factor.                                             Wnt signalling^36^                                        rs2076167
  *PPP2R4,* Protein phosphatase 2A activator, regulatory subunit 4                                                             Folding of proteins                                                       Wnt signalling^36^                                            NA
  ***TLE1*** **, Transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila)**                                        Transcriptional corepressor                                                   Wnt signalling^36^                                     rs2228173,rs8782
  ***WIF1*** **, Wnt inhibitory factor 1**                                                                               Inhibition of the WNT activities                                                Wnt signalling^36^                                   rs1026024,rs7301320
  *WNT1*, Wingless-type MMTV integration site family, member 1                                                      Ligand for members of the frizzled family                                            Wnt signalling^36^                                            NA
  ***BMP4*** **, Bone morphogenetic protein 4**                                                                       Induces cartilage and bone formation.                                              BMP signalling^17^                                         rs17563
  *BMPR1B*, Bone morphogenetic protein receptor, type IB                                                                  Transmembrane serine/threonine                                                 BMP signalling^17^                                            NA
  *SMAD1*, SMAD family member 1                                                                                                Signal transduction                                                       BMP signalling^17^                                            NA
  ***SMAD4*** **, SMAD family member 4**                                                                                       Signal transduction                                                       BMP signalling^17^                                        rs75667697
  *SMAD5*, SMAD family member 5                                                                                                Signal transduction                                                       BMP signalling^17^                                            NA
  ***SMURF1*** **, SMAD specific E3 ubiquitin protein ligase 1**                                                 Ubiquitination and degradation of SMAD proteins                                         BMP signalling^17^                                         rs219797
  ***AXIN2*** **, Axin 2**                                                                                                     B-catenin regulation                                             Wnt signalling, BMP induced genes^34^                              rs2240308
  ***CDH1*** **, Cadherin 1, type 1, E-cadherin**                                                                              B-catenin regulation                                             Wnt signalling, BMP induced genes^34^                              rs1801552
  ***CDH3*** **, Cadherin 3, type 1, P-cadherin (placental)**                                                                  B-catenin regulation                                             Wnt signalling, BMP induced genes^34^     rs1126933,rs17715450,rs2274239,rs2296408,rs2296409,rs8049247
  *DAB2*, Disabled homolog 2, mitogen-responsive phosphoprotein                                                                B-catenin regulation                                             Wnt signalling, BMP induced genes^34^                                  NA
  ***DACT1*** **, Dapper antagonist of beta-catenin, homolog 1 (Xenopus laevis)**                                              Disheveled inhibitor                                             Wnt signalling, BMP induced genes^34^                     rs17832998,rs698025,rs863091
  *KIFAP3*, Kinesin-associated protein 3                                                                                        Interacts with apc                                              Wnt signalling, BMP induced genes^34^                                  NA
  *LEF1*, Lymphoid enhancer-binding factor 1                                                                        Transcriptional activator of Wnt signaling                                  Wnt signalling, BMP induced genes^34^                                  NA
  ***TCF7*** **, Transcription factor 7 (T-cell specific, HMG-box)**                                                   transcriptional repressor of CTNNB1                                      Wnt signalling, BMP induced genes^34^                               rs30489
  ***WNT2B*** **, Wingless-type MMTV integration site family, member 2B**                                                           Wnt ligand                                                  Wnt signalling, BMP induced genes^34^                               rs910697
  *WNT5A*, Wingless-type MMTV integration site family, member 5A                                                                    Wnt ligand                                                  Wnt signalling, BMP induced genes^34^                                  NA
  *WNT5B*, Wingless-type MMTV integration site family, member 5B                                                                    Wnt ligand                                                  Wnt signalling, BMP induced genes^34^                                  NA

Genes finally screened are depicted in bold.

NA denotes not available SNPs for a given gene considering our selection criteria. rs4444235 and rs9929218 are not shown, for they were included because of their previous associations and not because they fulfilled our functional criteria.

rs4444235 and rs9929218 are two variants lying in the near-by and intronic regions of *BMP4* and *CDH1*, respectively, that have been recently reported to be associated with the disease [@pone.0012673-Houlston2]. Considering that the SNPs that we had chosen within these two genes were not good taggers for these two variants (r-squared values were 0.6 for the SNPs in *BMP4*, and 0.02 for those in *CHD1*) ([Figure 1](#pone-0012673-g001){ref-type="fig"}), we decided to include them in our study as well, although they did not fulfill our selection criteria, making the total number of interrogated SNPs rise to 45.

![Linkage disequilibrium blocks for the *BMP4* and *CDH1* genes.\
R-squared relationships between SNP pairs: A. rs4444235-rs17563 in *BMP4* and B. rs9929218-rs1801552 in *CDH1*.](pone.0012673.g001){#pone-0012673-g001}

Genotyping was performed with the MassARRAY (Sequenom Inc., San Diego, USA) technology at the Santiago de Compostela node of the Spanish Genotyping Center. Calling of genotypes was done with Sequenom Typer v4.0 software using all the data from the study simultaneously.

Statistical analyses {#s3f}
--------------------

Quality control was performed, first by excluding both SNPs and samples with genotype success rates below 95%, with the help of the Genotyping Data Filter (GDF) [@pone.0012673-Genotyping1]. Genotypic distributions for all SNPs in controls were consistent with Hardy-Weinberg equilibrium as assessed using a X^2^ test (1^df^). All p-values obtained were ≥0.05, thereby excluding the possibility of genotyping artifacts (data not shown). Population stratification was assessed with Structure v2.2 [@pone.0012673-Pritchard1]. Briefly, the posibility of different scenarios was tested assuming a different number of underlying populations (k ranging from 1 to 4), allowing for a large number of iterations (25 K in the burn-in period followed by 500 K repetitions). The mean log likelihood was estimated for the data for a given k (referred to as L(K)) in each run. We as well performed multiple runs for each value of k computing the overall mean L(K) and its standard deviation. All results seemed to be concordant with the original assumption of a single existing population. Moreover, additional procedures for better confounding variable visualization were undertaken by means of a Principal Component Analysis (PCA) using the EIGENSOFT tool *smartpca* [@pone.0012673-Patterson1], although number of markers was very low. No differences were found of population stratification between cases and controls for either STRUCTURE or the first 10 components of the PCA analysis ([Figure S2](#pone.0012673.s002){ref-type="supplementary-material"}). After quality control 1746 samples (854 cases and 892 controls) and 37 SNPs remained for further analyses.

Association tests were performed by chi-squared tests for every single SNP and haplotypes where possible with both Haploview v4.0 [@pone.0012673-Barrett1] and Unphased [@pone.0012673-Dudbridge1]. In short, LD patterns across genes for which more than one SNP was genotyped were checked in Haploview and tested for association using Unphased (to check in any of the haplotypes was associated) and Haploview (to see which of the haplotypes was associated). Genotypic association tests, logistic regression analysis for sex and age adjustment, and stratified analysis between sporadic and familial groups were estimated with PLINK v1.03 [@pone.0012673-Purcell1]. OR and 95% confidence intervals were calculated for each statistic, and to address the issue of multiple-testing, permutation tests and the Bonferroni correction were used. Study power was estimated with CATS software [@pone.0012673-Skol1].
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